comprehensive -WSS

comprehensive

author：explore 2025-08-11 11:43:58 - browse：925

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said Tuesday it would sell the company for less than $1 billion.

Alfasigma, an Italian pharmaceutical firm, will pay $19 a share for Intercept, in a roughly $800 million cash deal that represents an 80% premium to the company’s recent trading price. Intercept expects the deal to close by the end of the year.

The transaction comes three months after the Food and Drug Administration rejected Intercept’s treatment for NASH, an increasingly common fatty liver disease perceived as a potential gold mine by drug companies. Intercept’s medicine, called obeticholic acid, would have been the first approved treatment for NASH, but serious concerns about the risk of drug-related liver damage and uncertainty over whether its modest effects would improve patients’ lives made it unapprovable in the eyes of the FDA.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Readout Newsletter: Biotech news, including Moderna's Covid vaccine

WSS

Rep. Raul Ruiz on the physician shortage and more

How to pay for weight loss drugs and save Medicare

What don’t we know about an Alzheimer’s drug side effect?

Chemotherapy drug shortage eases slightly but still widespread

CDC director unscathed in first congressional testimony

3 questions for the future of Biden's cancer moonshot

hotspot

comprehensive

leisure time

Malaria cases in Florida and Texas: Here’s what you need to know

Analysis of telehealth claims data suggest service duplication

Trump demands the U.S. pay no more for drugs than other countries … again

Sana to lay off nearly a third of staff, de

Novavax promises a turnaround & Lilly roils the obesity market

Will the market for weight loss drugs really reach $100 billion?

Cancer drug shortages should be causing more outrage

Flagship Pioneering launches a new biotech in two countries

New air purifier tech could be key to improving indoor air quality

A Q&A with the global head of Boehringer Ingelheim's innovation unit

entertainment

What to do when lifesaving products contribute to climate change

VC firm General Catalyst wants to buy a health system

BIO selects John Crowley as new CEO

How to pay for weight loss drugs and save Medicare

How to pay for weight loss drugs and save Medicare

Physician executives need more than on

focus

focus

knowledge

Wikipedia